CLINICAL IMAGING

Molecular and anatomic imaging continues to be an ever increasing and essential component of clinical drug trials. Early stage trials examine target accessibility and drug pharmacokinetics, while later phase studies employ imaging as an early indicator of response or as an efficacy endpoint. New molecular probes from early phase studies become the future diagnostic agents that guide patient stratification for therapy and monitor patient response.


BioMolecular Imaging can also serve in an advisory role for venture investments in imaging companies and for merger and acquisition activities. We can provide investment advice and strategic support for start-ups or for mature companies, including those focused on development of new diagnostics, imaging hardware, or image analytics.

EARLY CLINICAL

petct_big1.jpg

Early clinical imaging examines factors such as organ penetration; drug target binding; biokinetics; and binding to sites for side effects and toxicity. These results stage the trial for subsequent extension or may result in stopping the trial, both of which have significant monetary implications.

LATE CLINICAL

molecular-imaging-01.jpg

Late clinical imaging trials are designed to examine biochemical and pharmacological correlates of clinical efficacy. Surrogate imaging biomarkers are also examined in late clinical trials. These aspects help make the case for drug approval and create a framework for patient treatment stratification and dosing.

 
 

We reached out to BioMolecular Imaging and Dr. Frost in the process of taking a new imaging agent from preclinical to clinical imaging. Dr. Frost identified several academic imaging institutions for the work and he did the initial vetting from the standpoint of capabilities and timing.

 
Business Meeting

ESSENTIALS

Molecular and anatomic imaging continues to be an ever increasing and essential component of clinical drug trials. Early stage trials examine target accessibility and drug pharmacokinetics, while later phase studies employ imaging as an early indicator of response or as an efficacy endpoint. New molecular probes from early phase studies become the future diagnostic agents that guide patient stratification for therapy and monitor patient response.

The truly staggering cost of drug development dictates that efficient practices must be employed at every development step. The use of quantifiable and objective imaging endpoints can form the basis of the needed process efficiencies, accelerating development and decreasing costs.

While imaging is an extremely powerful technology, it is a complex process itself. Most companies, however, don’t have the internal imaging expertise required to plan and carry out imaging studies. BioMolecular Imaging can help you to develop your company’s internal strategy; navigate imaging process steps to achieve tactical certainty; interface effectively with the necessary external partners; and maximize power of inference using best practice image analytics.

 

CONTACT BIOMOLECULAR IMAGING

Thanks for submitting!